Editorials

Are Physician-derived Joint Counts Obsolete?
E.C. Keystone .................................................. 883

Mismatch Between Skills of Patients and Tools in Use: Might Literacy Affect Diagnoses and Research?
R.E. Rudd .......................................................... 885

The Challenges of Quantifying the Risk of Serious Infection with Tumor Necrosis Factor Antagonist Therapy
J. Leombruno .................................................... 887

Atherosclerosis in Rheumatoid Arthritis: What to Look For in Studies Using Carotid Ultrasound
I. Del Rincon .................................................... 890

Review

More Night Than Day — Circadian Rhythms in Polymyalgia Rheumatica and Ankylosing Spondylitis
C.M. Spies, M. Cutolo, R.H. Straub, G-R. Burmester, F. Buttgereit .................. 894

Articles

Genetic Variations in Genes Encoding RANK, RANKL, and OPG in RA: A Case-Control Study
G. Assmann, J. Koenig, M. Pfleundschuh, et al. ......................................... 900


Decreased Circulating CD28– T Cells in Patients with RA Treated with Abatacept Are Correlated with Clinical Response
M. Scarsi, T. Ziglioli, P. Airò ........................................ 911

Efficacy and Safety of Retreatment in Patients with RA with Previous Inadequate Response to TNF Inhibitors: Results from the SUNRISE Trial
P.J. Mease, S. Cohen, N.B. Gaylis, et al. ............................................. 917

Observational Studies of Infections in RA: A Metaanalysis of TNF Antagonists
S. Bernatsky, Y. Habel, E. Rahme ......................................................... 928

Reproducibility of Joint Swelling Assessments in Long-lasting RA: Influence on Disease Activity Score-28 Values (SEA-Repro Study Part I)

Reproducibility of Joint Swelling Assessment by Sonography in Patients with Long-lasting RA (SEA-Repro Study Part II)
S. Jousse-Joulin, M.A. d’Agostino, T. Marhadour, et al. ......................... 938

Relationship Between Arterial Stiffness and Stanford HAQ Disability in RA Patients without Overt Arterial Disease
M.A. Crilly, H.J. Clark, V. Kumar, N.W. Scott, A.G. MacDonald, D.J. Williams .................. 946

Risk Factor Profiles for Atherosclerotic Cardiovascular Disease in Black and Other Africans with Established RA
A. Solomon, B.F. Christian, G.R. Norton, A.J. Woodwiss, P.H. Dessein ........................................... 953

Health Literacy Predicts the Discrepancy Between Patient and Provider Global Assessments of RA Activity at a Public Urban Rheumatology Clinic

Cytokine Profile of Macrophage Activation Syndrome Associated with Rheumatic Diseases
J. Maruyama, S. Inokuma .......................................................... 967

White-matter Volume Reduction and the Protective Effect of Immunosuppressive Therapy in SLE Patients with Normal Appearance by Conventional MRI
J. Xu, Y. Cheng, P. Chai, et al. ..................................................... 974

Phenotype-Haplotype Correlation of IRF5 in SSC: Role of 2 Haplotypes in Disease Severity
P. Dieudé, K. Dawidowicz, M. Guedj, et al. ............................................... 987

Early Detection of Cardiac Involvement in SSC Assessed by Tissue-Doppler Echocardiography: Relationship with Neurohormonal Activation and Endothelial Dysfunction

ILD Associated with Anti-PM/Sc1 or Anti-Aminoacyl-tRNA Synthetase Autoantibodies: A Similar Condition?
J.C. Lega, V. Cottin, N. Fabien, F. Thivolet-Bejui, J-F. Cordier ......................... 1000

Estimating Indirect Costs in Primary Sjögren’s Syndrome
S.J. Bowman, Y. St. Pierre, N. Sutcliffe, et al. ........................................ 1010

Influence of STAT4 Polymorphism in Primary Sjögren’s Syndrome

Lack of Association Between the rs6920220 (G/A) Polymorphism of the 6q23 Region and Biopsy-proven Giant Cell Arteritis

Minimally Important Difference for Patient-reported Outcomes in Psoriatic Arthritis: Health Assessment Questionnaire and Pain, Fatigue, and Global Visual Analog Scales
T. Kwok, J.E. Pope ......................................................... 1024

Serum Calprotectin as a Marker for Disease Activity and Severity in Adult-onset Still’s Disease

Patient-derived Joint Counts Are a Potential Alternative for Determining Disease Activity Score
Single-joint Outcome Measures: Preliminary Validation of Patient-reported Outcomes and Physical Examination
A.E. Heald, E.J. Fudman, P. Anklesaria, P.J. Mease, on behalf of the 13G01 Study Team .................................. 1042

Pediatric Rheumatology
Outcomes of Children Treated for Lyme Arthritis: Results of a Large Pediatric Cohort
H.O. Tory, D. Zurakowski, R.P. Sundel .................................. 1049

Images in Rheumatology
Cardiovascular MRI of Myocardial Fibrosis in DM
C. Arnold, H. Abdel-Aty, C. Tillmanns ................................. 1056
Intratendinous Power Doppler Changes Related to Patient Position in Seronegative Spondyloarthritis
M. Gutierrez, E. Filippucci, W. Grassi, M. Rosemffet .................. 1057
Bilateral Subcutaneous Patellar Calcifications and Unilateral Bursitis in Scleroderma
S. Mathieu, M. Soubrier, J-J. Dubost .................................. 1060

Correspondence
Irish Smokers with RA Suffer More Than Their Nonsmoking Counterparts
L.C. Harty, D.J. Veale .................................. 1062
Reply D.L. Mattay, A. Brownfield, P.T. Dawes ................... 1063
Race and MTX Pharmacogenetics in RA
P. Ranganathan, H. McLeod .................................. 1064
Reply M. Fisher, B. Cronstein .................................. 1064
Changes in Overall Health May Have Caused Recent Declines in ESR in Patients with RA
S.T. Anderson .................................. 1064
Reply T. Pincus, B. Abelzon, T. Sokka ................................. 1065
Tocilizumab for RA with Chronic Hepatitis B Virus Infection without Antiviral Therapy
T. Nagashima, S. Minota .................................. 1066
Reply D. Wendling .................................. 1066
Is Weight Loss an Effective Strategy to Decrease Serum Uric Acid Levels Without Use of Antihyperuricemic Medications?
D.J. Harris .................................. 1067

Association of RNA Polymerase III Antibodies with Scleroderma Renal Crisis
B. Nguyen, S. Assassi, F.C. Arnett, M.D. Mayes ......................... 1068
Reply V. Codullo, C. Montecucco .................................. 1069

Letters
Effects of Early Rituximab Retreatment in RA Patients with an Inadequate Response After the First Cycle: Retrospective Arthritis Cohort Study
Curious Crystals: Chylous Arthritis in RA
S. Rohekar .................................. 1072
Anti-TNF Therapies Reduce Serum Macrophage Inflammatory Protein-1α in Ankylosing Spondylitis
H. Akbulut, S.S. Koca, M. Ozgen, A. Isik .................................. 1073
Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
K. Hagihara, I. Kawase, T. Tanaka, T. Kishimoto .................. 1075
Acute Pseudogout Following Intravenous Neridronate for Osteoporosis
S. Carda, M. Iverini, P.P. Sainaghi, C. Cisari .................................. 1076
Bosentan-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome
Y. Allanore, L. Moachon, E. Maury, A. Isvy, A. Kahan .................................. 1077
Scourvy as the Presenting Illness of Whipple’s Disease Exacerbated by Treatment with Etanercept in a Patient with Ankylosing Spondylitis
I. Hmamouchi, V. Costes, B. Combe, J. Morel .................................. 1078
Successful Use of Adalimumab for Treating RA with Autoimmune Sensorineural Hearing Loss: Two Birds with One Stone
J.M. Vergles, M. Radic, J. Kovacic, L. Salamon .................................. 1080

Correction
Less Radiographic Progression with Adalimumab plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis
Meetings in Rheumatology ..................................